Adjunctive Everolimus Treatment of Refractory Epilepsy
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This project is a prospective, randomized, placebo-controlled, double-blind study that will
evaluate the clinical efficacy of everolimus as an adjunctive treatment in adult patients
diagnosed with refractory epilepsy.